ERA-Based 40-Hz ASSR Biomarkers in Mood and Psychotic Disorders

ERA Systems Detect Neural Synchrony Deficits Across Major Psychiatric Disorders

Evoked response audiometry (ERA) systems, already widely available in clinical neurophysiology, can reliably detect deficits in neural synchrony—specifically, phase delay and phase-locking abnormalities in the 40-Hz auditory steady-state response (ASSR)—in individuals with schizophrenia, bipolar disorder, and major depressive disorder. This extends the established use of 40-Hz ASSR as a biomarker in schizophrenia to a broader spectrum of mood and psychotic disorders, according to a peer-reviewed study published on September 1, 2026 (OpenAlex W7204912169).

The study evaluated 107 participants, including patients with schizophrenia (n=29), bipolar disorder (n=24), major depressive disorder (n=25), and healthy controls (n=29). All clinical groups exhibited significant phase delays in the 40-Hz ASSR compared to controls. Notably, nonphase-locked responses (NPLR)—previously considered more specific to schizophrenia—were also present in subsets of bipolar and major depressive disorder patients, indicating a shared neurophysiological signature across diagnostic boundaries.

Mechanistic Insights: Gamma Synchrony and the 40-Hz ASSR

The 40-Hz ASSR is a robust measure of gamma-band neural synchrony, reflecting the brain's ability to coordinate neural firing at frequencies critical for perception, cognition, and mood regulation. Impaired gamma synchrony has been implicated in the pathophysiology of schizophrenia, and emerging evidence now links similar deficits to mood disorders, suggesting convergent disruptions in cortical circuitry.

ERA systems deliver periodic auditory stimuli and record the brain's electrical response, providing a practical, noninvasive, and scalable method for quantifying neural synchrony. The present study's demonstration that phase delay and NPLR can be measured in individual patients with mood and psychotic disorders—using equipment already present in many clinics—lowers the barrier to large-scale biomarker deployment in both research and clinical settings.

Implications for Psychedelic Trials and Precision Psychiatry

ERA-based 40-Hz ASSR profiling offers a pragmatic pathway to biomarker-driven patient stratification and outcome measurement in psychiatric research, including psychedelic clinical trials. Psychedelic compounds such as psilocybin and ketamine are being evaluated for treatment-resistant depression, bipolar disorder, and schizophrenia in trials registered with the U.S. National Institutes of Health (ClinicalTrials.gov). However, heterogeneous patient populations and subjective endpoints have hampered reproducibility and regulatory acceptance.

By enabling objective, physiology-based subgrouping of participants—such as identifying those with pronounced gamma synchrony deficits—ERA-based biomarkers could improve trial design, enhance statistical power, and facilitate the development of precision therapeutics. This approach aligns with recent U.S. Food and Drug Administration (FDA) guidance encouraging the integration of digital and electrophysiological biomarkers in psychiatric drug development (FDA DHT Qualification).

• Scalability: ERA systems are less expensive and more accessible than advanced neuroimaging, supporting deployment in diverse research and clinical settings.
• Regulatory relevance: Objective biomarkers may accelerate approval timelines and support claims of efficacy or mechanism in psychedelic trials.

Risks, Limitations, and Unknowns

ERA-based 40-Hz ASSR profiling, while promising, presents several limitations and open questions. First, the specificity of phase delay and NPLR to particular diagnoses is limited: the same neural signature appears across schizophrenia, bipolar disorder, and major depression, complicating its use as a diagnostic tool. Second, the relationship between ASSR abnormalities and symptom severity, treatment response, or long-term outcomes remains to be established in larger, longitudinal studies.

Another underappreciated risk is the potential for misclassification or overinterpretation of NPLR status in heterogeneous clinical samples, particularly if ERA protocols are not standardized across sites. False positives or negatives could undermine the reliability of biomarker-driven stratification. Additionally, while ERA systems are widely available, operator training and quality assurance are critical to ensure reproducibility—an insight often overlooked in the rush to scale pragmatic biomarkers.

Outlook: Toward Scalable Biomarkers in Psychiatric and Psychedelic Research

ERA-based 40-Hz ASSR profiling represents a concrete advance toward scalable, objective biomarkers for mood and psychotic disorders. Its extension beyond schizophrenia to bipolar disorder and major depression supports a transdiagnostic, circuit-based approach to psychiatric research—a key paradigm shift for both conventional and psychedelic drug development.

Future research should prioritize multicenter validation, harmonization of ERA protocols, and integration of ASSR measures with clinical, genetic, and digital phenotyping data. If successful, this approach could improve patient selection, outcome measurement, and mechanistic understanding in the next generation of psychiatric and psychedelic trials, ultimately enhancing clinical translation and public health impact.

How we research: Reviewed and interpreted by Dr. Alex M. Feldman, MD, PhD (psychiatry, neurophysiology). Reviewed September 2026. Primary sources: OpenAlex W7204912169, FDA, ClinicalTrials.gov.